Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleEffective treatment of spasticity using dronabinol in pediatric palliative care.
Author(s)Kuhlen M, Hoell JI, Gagnon G, Balzer S, Oommen PT, Borkhardt A, Jan▀en G.
Journal, Volume, IssueEur J Paediatr Neurol. 2016 Nov;20(6):898-903. doi: 10.1016/j.ejpn.2016.07.021. Epub 2016 Jul 30.
Major outcome(s)In the majority of pediatric palliative patients the treatment with dronabinol showed promising effects in treatment resistant spasticit.
IndicationSpasticityAbstract
MedicationDelta-9-THC

BACKGROUND: Cannabis extracts have a wide therapeutic potential but in many countries they have not been approved for treatment in children so far. OBJECTIVE: We conducted an open, uncontrolled, retrospective study on the administration of dronabinol to determine the value, efficacy, and safety of cannabis-based medicines in the treatment of refractory spasticity in pediatric palliative care. DESIGN AND PARTICIPANTS: Sixteen children, adolescents and young adults having complex neurological conditions with spasticity (aged 1.3-26.6 years, median 12.7 years) were treated with dronabinol by our specialized pediatric palliative care team between 01.12.2010 and 30.04.2015 in a home-care setting. Therapeutic efficacy and side effects were closely monitored. RESULTS: Drops of the 2.5% oily tetrahydrocannabinol solution (dronabinol) were administered. A promising therapeutic effect was seen, mostly due to abolishment or marked improvement of severe, treatment resistant spasticity (n = 12). In two cases the effect could not be determined, two patients did not benefit. The median duration of treatment was 181 days (range 23-1429 days). Dosages to obtain a therapeutic effect varied from 0.08 to 1.0 mg/kg/d with a median of 0.33 mg/kg/d in patients with a documented therapeutic effect. When administered as an escalating dosage scheme, side effects were rare and only consisted in vomiting and restlessness (one patient each). No serious and enduring side effects occurred even in young children and/or over a longer period of time. CONCLUSIONS: In the majority of pediatric palliative patients the treatment with dronabinol showed promising effects in treatment resistant spasticity.

Route(s)Oral
Dose(s)0.08 to 1.0 mg THC per kg body weight
Duration (days)181 days (range 23-1429 days)
ParticipantsSixteen children, adolescents and young adults having comple
Design
Type of publicationMedical journal
Address of author(s)University of Dusseldorf, Medical Faculty, Department of Pediatric Oncology, Hematology and Clinical Immunology, Center for Child and Adolescent Health, Moorenstr. 5, 40225 Dusseldorf, Germany. Electronic address: michaela.kuhlen@med.uni-duesseldorf.de.
Full texthttps://www.ncbi.nlm.nih.gov/pubmed/?term=27506815

[Back to Overview]  [IACM Homepage]


up